Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Brian Ball

Assistant Clinical Professor

City of Hope

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

About

Brian Ball is an Assistant Clinical Professor at City of Hope in the United States. His research primarily focuses on hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. Recent articles authored by Professor Ball examine healthcare resource utilization associated with treatment modalities and the clinical implications of genetic mutations in these conditions.

Articles (9)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (1)

Yasmin Abaza

Assistant Professor of Medicine

Northwestern Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Brian Ball

Research Interests

Explore related searches

About

Articles (9)

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure

Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study

Hypomethylating agents–venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT

Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

High prevalence and inferior long‐term outcomes for TP53 mutations in therapy‐related acute lymphoblastic leukemia

The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Collaborators (1)

Yasmin Abaza

Make your next move.